Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immunogenicity and Safety of Rotavac and Rotasiil Administered in an Interchangeable Dosing Schedule among Healthy Indian Infants: A Multicentric, Phase IV, Open-Labeled, Randomized, Controlled Trial - RVICS

Next Previous
Trial Profile

Immunogenicity and Safety of Rotavac and Rotasiil Administered in an Interchangeable Dosing Schedule among Healthy Indian Infants: A Multicentric, Phase IV, Open-Labeled, Randomized, Controlled Trial - RVICS

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bovine rotavirus vaccine reassortant (Primary) ; ORV 116E (Primary)
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Acronyms RVICS

    • Most Recent Events

    • 01 Aug 2022 Results (n=1979; Between March 25, 2019, and Jan 15, 2020) assessing the safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants, published in The Lancet Infectious Diseases.
    • 05 Nov 2019 Status changed from not yet recruiting to recruiting.
    • 13 Nov 2018 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top